pSivida Corp

Press Releases

All Releases
View Summary Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy
Jul 20, 2016
PDF 19.4 KB Add to Briefcase
View Summary pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility
Jul 15, 2016
PDF 16.8 KB Add to Briefcase
View Summary Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
Jul 14, 2016
PDF 20.2 KB Add to Briefcase
View Summary pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
Jul 8, 2016
PDF 16.7 KB Add to Briefcase
View Summary pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Jul 5, 2016
PDF 18.3 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 5, 2016
PDF 34.6 KB Add to Briefcase
View Summary pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 4, 2016
PDF 16.4 KB Add to Briefcase
View Summary pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
May 2, 2016
PDF 17.4 KB Add to Briefcase
View Summary pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Apr 27, 2016
PDF 16.4 KB Add to Briefcase
View Summary pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
Mar 24, 2016
PDF 16.4 KB Add to Briefcase
View Summary Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
Mar 15, 2016
PDF 20.0 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
Feb 8, 2016
PDF 35.3 KB Add to Briefcase
View Summary pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Feb 1, 2016
PDF 16.5 KB Add to Briefcase
View Summary pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
Jan 28, 2016
PDF 17.3 KB Add to Briefcase
View Summary pSivida Closes $17.8 Million Offering
Jan 13, 2016
PDF 14.7 KB Add to Briefcase
View Summary pSivida Announces Pricing of $16 Million Public Offering of Common Stock
Jan 7, 2016
PDF 14.3 KB Add to Briefcase
View Summary pSivida Announces Proposed Public Offering of Common Stock
Jan 6, 2016
PDF 14.8 KB Add to Briefcase
View Summary pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 28, 2015
PDF 20.6 KB Add to Briefcase
View Summary pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Dec 22, 2015
PDF 27.6 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Nov 5, 2015
PDF 32.6 KB Add to Briefcase
Showing 21-40 of 270 Page: 1 2 3 4 5 6 ... 14  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Search Investor Relations

pSivida